See more : Vection Technologies Limited (VCTTF) Income Statement Analysis – Financial Results
Complete financial analysis of Phibro Animal Health Corporation (PAHC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Phibro Animal Health Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Mu Global Holding Limited (MUGH) Income Statement Analysis – Financial Results
- Yongyue Science&Technology Co.,Ltd (603879.SS) Income Statement Analysis – Financial Results
- Myers Industries, Inc. (MYE) Income Statement Analysis – Financial Results
- Bitcoin Well Inc. (BTCW.V) Income Statement Analysis – Financial Results
- Osaka Gas Co., Ltd. (OSGSF) Income Statement Analysis – Financial Results
Phibro Animal Health Corporation (PAHC)
About Phibro Animal Health Corporation
Phibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.02B | 977.89M | 942.30M | 833.40M | 800.40M | 828.00M | 820.00M | 764.30M | 751.50M | 748.59M | 691.90M | 653.15M | 654.10M | 618.33M | 594.20M | 537.10M | 511.40M | 453.00M | 398.40M | 364.40M | 354.40M | 337.80M | 328.70M | 319.70M | 323.00M |
| Cost of Revenue | 704.59M | 679.65M | 656.90M | 562.00M | 543.50M | 563.40M | 553.10M | 516.00M | 512.50M | 512.22M | 484.10M | 474.19M | 489.96M | 471.67M | 439.50M | 407.50M | 389.70M | 341.80M | 307.30M | 293.10M | 265.20M | 248.60M | 247.40M | 250.30M | 249.60M |
| Gross Profit | 313.09M | 298.24M | 285.40M | 271.40M | 256.90M | 264.60M | 266.90M | 248.30M | 239.00M | 236.37M | 207.80M | 178.96M | 164.14M | 146.67M | 154.70M | 129.60M | 121.70M | 111.20M | 91.10M | 71.30M | 89.20M | 89.20M | 81.30M | 69.40M | 73.40M |
| Gross Profit Ratio | 30.77% | 30.50% | 30.29% | 32.57% | 32.10% | 31.96% | 32.55% | 32.49% | 31.80% | 31.58% | 30.03% | 27.40% | 25.09% | 23.72% | 26.04% | 24.13% | 23.80% | 24.55% | 22.87% | 19.57% | 25.17% | 26.41% | 24.73% | 21.71% | 22.72% |
| Research & Development | 29.19M | 24.40M | 20.83M | 17.76M | 13.74M | 12.08M | 10.00M | 9.44M | 11.03M | 9.51M | 8.21M | 6.64M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 101.90M | 84.60M | 81.30M | 76.20M | 68.10M | 66.90M | 63.40M | 63.30M | 70.60M | 63.90M | 59.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 220.88M | 226.39M | 206.40M | 196.50M | 187.70M | 181.40M | 168.00M | 150.30M | 153.30M | 148.70M | 144.00M | 122.23M | 114.81M | 105.43M | 101.90M | 84.60M | 81.30M | 76.20M | 68.10M | 66.90M | 63.40M | 63.30M | 70.60M | 63.90M | 59.30M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -151.00K | 400.00K | -593.00K | 0.00 | 3.60M | 11.10M | 14.00M | 0.00 | 0.00 | -17.90M | 0.00 | 0.00 | 0.00 | -1.50M |
| Operating Expenses | 260.30M | 226.39M | 206.40M | 196.50M | 187.70M | 181.40M | 168.00M | 150.30M | 153.30M | 148.70M | 144.00M | 122.23M | 114.81M | 105.43M | 101.90M | 88.20M | 92.40M | 90.20M | 68.10M | 66.90M | 45.50M | 63.30M | 70.60M | 63.90M | 57.80M |
| Cost & Expenses | 964.36M | 906.04M | 863.30M | 758.50M | 731.20M | 744.80M | 721.10M | 666.30M | 665.80M | 660.92M | 628.10M | 596.42M | 604.78M | 577.10M | 541.40M | 495.70M | 482.10M | 432.00M | 375.40M | 360.00M | 310.70M | 311.90M | 318.00M | 314.20M | 307.40M |
| Interest Income | 4.47M | 3.36M | 816.00K | 838.00K | 1.76M | 1.90M | 1.69M | 1.97M | 256.00K | 249.00K | 119.00K | 142.00K | 281.00K | 307.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 21.97M | 17.95M | 11.90M | 12.90M | 12.90M | 11.80M | 11.90M | 14.90M | 16.60M | 14.55M | 33.00M | 35.77M | 35.70M | 34.60M | -33.10M | -43.40M | -26.90M | -27.30M | -32.60M | -26.90M | -20.60M | -17.40M | -17.70M | -17.70M | -14.20M |
| Depreciation & Amortization | 36.18M | 34.01M | 32.71M | 31.89M | 32.34M | 27.56M | 26.94M | 26.00M | 23.45M | 21.60M | 21.45M | 19.02M | 17.53M | 16.70M | -40.00M | -89.70M | -51.40M | 10.72M | 13.99M | 18.11M | 10.66M | 10.99M | 12.36M | 10.41M | 11.87M |
| EBITDA | 84.61M | 116.63M | 114.82M | 105.50M | 102.16M | 112.75M | 128.62M | 123.42M | 117.06M | 114.92M | 60.84M | 72.64M | 66.34M | 43.40M | 12.80M | -48.30M | -22.10M | -22.88M | -26.51M | -28.79M | 10.76M | -14.21M | -42.34M | -22.59M | 11.67M |
| EBITDA Ratio | 8.31% | 11.09% | 8.38% | 8.99% | 8.65% | 10.07% | 12.06% | 12.81% | 11.42% | 14.63% | 9.24% | 11.60% | 10.32% | 9.32% | 2.15% | -8.99% | -4.32% | -5.05% | -6.65% | -7.90% | 3.04% | -4.21% | -12.88% | -7.07% | 3.61% |
| Operating Income | 53.32M | 71.85M | 46.30M | 43.02M | 36.86M | 73.30M | 98.90M | 97.90M | 85.70M | 87.67M | 63.80M | 56.73M | 49.33M | 41.24M | 52.80M | 41.40M | 29.30M | 21.10M | 23.00M | 4.40M | 43.70M | 25.90M | 10.60M | 5.40M | 15.70M |
| Operating Income Ratio | 5.24% | 7.35% | 4.91% | 5.16% | 4.61% | 8.85% | 12.06% | 12.81% | 11.40% | 11.71% | 9.22% | 8.69% | 7.54% | 6.67% | 8.89% | 7.71% | 5.73% | 4.66% | 5.77% | 1.21% | 12.33% | 7.67% | 3.22% | 1.69% | 4.86% |
| Total Other Income/Expenses | -42.40M | -17.78M | -6.66M | -8.40M | -13.68M | -11.72M | -10.86M | -17.39M | -19.44M | -8.91M | -57.49M | -38.88M | -36.21M | -49.13M | -33.20M | -43.50M | -27.40M | -27.40M | -30.90M | -25.80M | -19.80M | -18.90M | -21.00M | -17.10M | -1.70M |
| Income Before Tax | 10.92M | 54.07M | 72.30M | 66.50M | 55.50M | 71.50M | 88.10M | 80.50M | 76.80M | 78.76M | 6.30M | 17.85M | 13.11M | -7.89M | 19.60M | -2.10M | 1.90M | -6.30M | -7.90M | -21.40M | 23.90M | 7.00M | -10.40M | -11.70M | 14.00M |
| Income Before Tax Ratio | 1.07% | 5.53% | 7.67% | 7.98% | 6.93% | 8.64% | 10.74% | 10.53% | 10.22% | 10.52% | 0.91% | 2.73% | 2.00% | -1.28% | 3.30% | -0.39% | 0.37% | -1.39% | -1.98% | -5.87% | 6.74% | 2.07% | -3.16% | -3.66% | 4.33% |
| Income Tax Expense | 8.50M | 21.47M | 23.20M | 12.10M | 22.00M | 16.80M | 23.20M | 15.90M | -6.00M | 18.48M | 9.40M | -7.04M | 6.14M | 5.03M | 3.80M | 3.40M | 2.60M | 400.00K | 5.20M | 2.10M | 7.80M | 9.80M | 14.80M | -400.00K | 3.90M |
| Net Income | 2.42M | 32.61M | 49.18M | 54.39M | 33.55M | 54.70M | 64.90M | 64.60M | 82.70M | 60.28M | -3.10M | 24.89M | 6.98M | -12.92M | 42.10M | -8.30M | 2.20M | -6.70M | -13.10M | -22.10M | 12.90M | -17.60M | -51.80M | -14.90M | 10.10M |
| Net Income Ratio | 0.24% | 3.33% | 5.22% | 6.53% | 4.19% | 6.61% | 7.91% | 8.45% | 11.00% | 8.05% | -0.45% | 3.81% | 1.07% | -2.09% | 7.09% | -1.55% | 0.43% | -1.48% | -3.29% | -6.06% | 3.64% | -5.21% | -15.76% | -4.66% | 3.13% |
| EPS | 0.06 | 0.81 | 1.21 | 1.34 | 0.83 | 1.35 | 1.61 | 1.63 | 2.11 | 1.55 | -0.10 | 0.82 | 0.23 | -0.42 | 1.09 | -0.21 | 0.06 | -0.17 | -0.22 | -0.37 | 0.22 | -0.29 | -0.86 | -0.25 | 0.17 |
| EPS Diluted | 0.06 | 0.81 | 1.21 | 1.34 | 0.83 | 1.35 | 1.61 | 1.61 | 2.07 | 1.51 | -0.10 | 0.82 | 0.23 | -0.42 | 1.09 | -0.21 | 0.06 | -0.17 | -0.22 | -0.37 | 0.22 | -0.29 | -0.86 | -0.25 | 0.17 |
| Weighted Avg Shares Out | 40.50M | 40.50M | 40.50M | 40.47M | 40.45M | 40.41M | 40.20M | 39.50M | 39.30M | 38.97M | 31.27M | 30.46M | 30.46M | 30.46M | 38.80M | 38.80M | 38.80M | 38.80M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M |
| Weighted Avg Shares Out (Dil) | 40.52M | 40.50M | 40.50M | 40.50M | 40.50M | 40.52M | 40.40M | 40.00M | 40.00M | 39.82M | 32.20M | 30.46M | 30.53M | 30.46M | 38.80M | 38.80M | 38.80M | 38.80M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M | 60.00M |
4 Medical Product Stocks to Buy From a Prospective Industry
Reasons to Add Phibro Stock to Your Portfolio Right Now
Here is Why Growth Investors Should Buy Phibro (PAHC) Now
Why Phibro Animal Health (PAHC) is a Top Momentum Stock for the Long-Term
PAHC vs. ABT: Which Stock Is the Better Value Option?
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
Looking for a Growth Stock? 3 Reasons Why Phibro (PAHC) is a Solid Choice
Phibro Animal Health Corporation (PAHC) Hits Fresh High: Is There Still Room to Run?
Investing in Phibro (PAHC)? Don't Miss Assessing Its International Revenue Trends
Phibro Animal Health Corporation (PAHC) Q1 2025 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports